Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Seres Therapeutics, Inc. (“Seres” or the “Company”) (NASDAQ: MCRB) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.

Seres is a microbiome therapeutics platform company that focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome.

On July 29, 2016, Seres disclosed that its Phase 2 clinical study for ECOSPOR™ did not meet its primary endpoint of reducing the relative risk of Clostridium difficle infection recurrence. On this news, Seres shares fell sharply, as much as 76%, on August 1, 2016.

Additionally, just a couple days prior to this announcement, the Company’s President, CEO and Chairman of the Board sold 20,000 shares of Seres at $35 per share, and another Company insider sold 38,064 shares at $35.12 per share.

If you purchased Seres securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161007005676/en/